Bristol-Myers Squibb: new developments at ASCO meeting.
(CercleFinance.com) - Bristol-Myers Squibb today disclosed data from a phase 1/2 study evaluating Opdivo for the treatment of cancers associated with infection by the human papillomavirus (HPV).
The preliminary efficacy measures on a cohort that included 24 patients with advanced cervical, vaginal and vulvar cancers, showed an objective response rate of 20.8% with a 70.8% rate of women experiencing complete or partial response or stable disease, the company said.
HPV, which is transmitted through sexual contact, is linked to over 90% of cervical cancers, about 75% of vaginal cancers and 69% of vulvar cancers.
Bristol-Myers Squibb also said that it has entered into a collaboration agreement to evaluate the combination of Opdivo with Seattle Genetics' antibody Adcetris in advanced classical Hodgkin lymphoma (HL).
These two announcements were made as the meeting of the American Society of Clinical Oncology (ASCO) kicks off today in Chicago.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The preliminary efficacy measures on a cohort that included 24 patients with advanced cervical, vaginal and vulvar cancers, showed an objective response rate of 20.8% with a 70.8% rate of women experiencing complete or partial response or stable disease, the company said.
HPV, which is transmitted through sexual contact, is linked to over 90% of cervical cancers, about 75% of vaginal cancers and 69% of vulvar cancers.
Bristol-Myers Squibb also said that it has entered into a collaboration agreement to evaluate the combination of Opdivo with Seattle Genetics' antibody Adcetris in advanced classical Hodgkin lymphoma (HL).
These two announcements were made as the meeting of the American Society of Clinical Oncology (ASCO) kicks off today in Chicago.
Copyright (c) 2017 CercleFinance.com. All rights reserved.